ArticleNature communications2024
Reciprocal antagonism of PIN1-APC/C
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Self-synergizing mutual prodrug liposomes for targeted cancer therapyTheranostics · 2026Article
- Cyclin B2 facilitates glycolysis and tumor progression in pancreatic ductal adenocarcinoma by promoting histone lactylation.BMC cancer · 2025Article
- BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells.Journal of neuroinflammation · 2025Article
- LncRNA938/ TAF9/TTK axis promotes EMT and serves as a therapeutic target in hepatoblastoma.Journal of translational medicine · 2025Article
- Molecular targets of neuroplasticity in ischemic stroke: insights from GEO database, single-cell analysis and immune infiltration analysis.Frontiers in aging neuroscience · 2025Article
- Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery.Science signaling · 2024Review
- Review
- The role of the master cancer regulator Pin1 in the development and treatment of cancer.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 2 countries.
Shizhong Ke *Division of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Fabin Dang *Department of Pathology, Beth Israel Deaconess Medical Center and Cancer Research Institute, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-1954-8231
Lin Wang *Division of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-2061-4224
Jia-Yun Chen *Department of Systems Biology, Harvard Medical School, Boston, MA, 02215, USA.
Mandar T NaikDepartment of Molecular Biology, Cell Biology & Biochemistry, Brown University, Providence, RI, 02912, USA.
Wenxue LiYale Cancer Biology Institute, West Haven, CT, 06516, USA.ORCID http://orcid.org/0000-0002-8902-0184
Abhishek ThavamaniDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Nami KimDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Nandita M NaikDepartment of Molecular Biology, Cell Biology & Biochemistry, Brown University, Providence, RI, 02912, USA.
Huaxiu SuiKey Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen, 361023, China.
Wei TangData Science & Artificial Intelligence, R&D, AstraZeneca, Gaithersburg, MD, USA.
Chenxi QiuDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Kazuhiro KoikawaDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Felipe BataliniDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0003-3354-308X
Emily Stern GatofDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Daniela Arango IsazaDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Jaymin M PatelDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0001-9945-5555
Xiaodong WangMolecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, 02215, USA.
John G ClohessyPreclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0001-5186-9775
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center and Cancer Research Institute, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-8930-817X
Galit LahavDepartment of Systems Biology, Harvard Medical School, Boston, MA, 02215, USA.
Yansheng LiuYale Cancer Biology Institute, West Haven, CT, 06516, USA.ORCID http://orcid.org/0000-0002-2626-3912
Nathanael S GrayDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-5354-7403
Xiao Zhen ZhouDepartments of Pathology and Laboratory Medicine, Biochemistry, and Oncology, and Lawson Health Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, N6A 3K7, Canada. xzhou659@uwo.ca.
Wenyi WeiDepartment of Pathology, Beth Israel Deaconess Medical Center and Cancer Research Institute, Harvard Medical School, Boston, MA, 02215, USA. wwei2@bidmc.harvard.edu.
Gerburg M WulfDivision of Hematology/Oncology, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. gwulf@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-7868-6231
Kun Ping LuDepartments of Biochemistry and Oncology, and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, N6A 3K7, Canada. klu92@uwo.ca.ORCID http://orcid.org/0000-0002-0734-1567
Beth Israel Deaconess Medical Center · USBrown University · USHarvard University · USWestern University · CAYale Cancer Center · USAstraZeneca (United States) · USStanford University · USXiamen Medical College
Funding
Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI Nabihah Tayob · 2013 to 2026
$30.1MDeciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapiesR35CA253027 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wenyi Wei · 2020 to 2026
$6.2MDynamics, Regulation and Function of p53 in Single CellsR35GM139572 · NIGMS · HARVARD MEDICAL SCHOOL · PI Galit Lahav · 2021 to 2026
$4.7MRole of Tau Conformations in Vascular Contribution to Cognitive Impairment and DementiaR01AG055559 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LO, ENG H., SHEHADAH, AMJAD · 2017 to 2021
$3.4MDevelopment of selective Pin1 inhibitors to target a common oncogenic mechanismR01CA205153 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRAY, NATHANAEL SCHIANDER, WULF, GERBURG M · 2017 to 2021
$3.3MOptimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapyR01CA226776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WULF, GERBURG M · 2018 to 2022
$2.1MUnderstanding proteome remodeling in aneuploidyR01GM137031 · NIGMS · YALE UNIVERSITY · PI LIU, YANSHENG · 2020 to 2024
$2.0MNovel regulation of the CDK4/Cdh1/Pin1 signaling axis for targeted breast cancer therapiesK99CA263194 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI DANG, FABIN · 2021 to 2022
$340kNCI NIH HHS K99 CA263194NCI NIH HHS P50 CA168504NCI NIH HHS R01 CA205153NCI NIH HHS R01 CA226776NCI NIH HHS R35 CA253027NIA NIH HHS R01 AG055559NIGMS NIH HHS R01 GM137031NIGMS NIH HHS R35 GM139572
Abstract
Induced oncoproteins degradation provides an attractive anti-cancer modality. Activation of anaphase-promoting complex (APC/C
Indexed as
Cell Cycle ProteinsProteomicsAnaphase-Promoting Complex-CyclosomeCell CycleMitosisNIMA-Interacting Peptidylprolyl IsomerasePhosphorylationProtein StabilityAnaphase-Promoting Complex-CyclosomeCell Cycle ProteinsNIMA-Interacting Peptidylprolyl Isomerase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.